Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 87

1.

Integrin alpha-5 subunit is critical for the early stages of human pluripotent stem cell cardiac differentiation.

Neiman G, Scarafía MA, La Greca A, Santín Velazque NL, Garate X, Waisman A, Möbbs AM, Kasai-Brunswick TH, Mesquita F, Martire-Greco D, Moro LN, Luzzani C, Bastos Carvalho A, Sevlever GE, Campos de Carvalho A, Guberman AS, Miriuka SG.

Sci Rep. 2019 Dec 2;9(1):18077. doi: 10.1038/s41598-019-54352-2.

2.

Silencing of the transcription factors Oct4, Sox2, Klf4, c-Myc or Nanog has different effect on teratoma growth.

Villodre ES, Felipe KB, Oyama MZ, Oliveira FH, Lopez PLDC, Solari C, Sevlever G, Guberman A, Lenz G.

Biochem Biophys Res Commun. 2019 Sep 17;517(2):324-329. doi: 10.1016/j.bbrc.2019.07.064. Epub 2019 Jul 25.

PMID:
31353083
3.

A dose-dependent response to MEK inhibition determines hypoblast fate in bovine embryos.

Canizo JR, Ynsaurralde Rivolta AE, Vazquez Echegaray C, Suvá M, Alberio V, Aller JF, Guberman AS, Salamone DF, Alberio RH, Alberio R.

BMC Dev Biol. 2019 Jul 4;19(1):13. doi: 10.1186/s12861-019-0193-9.

4.

The pluripotency transcription factor Nanog represses glutathione reductase gene expression in mouse embryonic stem cells.

Solari C, Petrone MV, Toro A, Vazquez Echegaray C, Cosentino MS, Waisman A, Francia M, Barañao L, Miriuka S, Guberman A.

BMC Res Notes. 2019 Jul 1;12(1):370. doi: 10.1186/s13104-019-4411-0.

5.

Cell cycle dynamics of mouse embryonic stem cells in the ground state and during transition to formative pluripotency.

Waisman A, Sevlever F, Elías Costa M, Cosentino MS, Miriuka SG, Ventura AC, Guberman AS.

Sci Rep. 2019 May 29;9(1):8051. doi: 10.1038/s41598-019-44537-0.

6.

Deep Learning Neural Networks Highly Predict Very Early Onset of Pluripotent Stem Cell Differentiation.

Waisman A, La Greca A, Möbbs AM, Scarafía MA, Santín Velazque NL, Neiman G, Moro LN, Luzzani C, Sevlever GE, Guberman AS, Miriuka SG.

Stem Cell Reports. 2019 Apr 9;12(4):845-859. doi: 10.1016/j.stemcr.2019.02.004. Epub 2019 Mar 14.

7.

Kat6b Modulates Oct4 and Nanog Binding to Chromatin in Embryonic Stem Cells and Is Required for Efficient Neural Differentiation.

Cosentino MS, Oses C, Vázquez Echegaray C, Solari C, Waisman A, Álvarez Y, Petrone MV, Francia M, Schultz M, Sevlever G, Miriuka S, Levi V, Guberman A.

J Mol Biol. 2019 Mar 15;431(6):1148-1159. doi: 10.1016/j.jmb.2019.02.012. Epub 2019 Feb 18.

PMID:
30790630
8.

Extracellular vesicles from pluripotent stem cell-derived mesenchymal stem cells acquire a stromal modulatory proteomic pattern during differentiation.

La Greca A, Solari C, Furmento V, Lombardi A, Biani MC, Aban C, Moro L, García M, Guberman AS, Sevlever GE, Miriuka SG, Luzzani C.

Exp Mol Med. 2018 Sep 10;50(9):119. doi: 10.1038/s12276-018-0142-x.

9.

Exogenous human OKSM factors maintain pluripotency gene expression of bovine and porcine iPS-like cells obtained with STEMCCA delivery system.

Canizo JR, Vazquez Echegaray C, Klisch D, Aller JF, Paz DA, Alberio RH, Alberio R, Guberman AS.

BMC Res Notes. 2018 Jul 27;11(1):509. doi: 10.1186/s13104-018-3627-8.

10.

Superoxide dismutase 1 expression is modulated by the core pluripotency transcription factors Oct4, Sox2 and Nanog in embryonic stem cells.

Solari C, Petrone MV, Vazquez Echegaray C, Cosentino MS, Waisman A, Francia M, Barañao L, Miriuka S, Guberman A.

Mech Dev. 2018 Dec;154:116-121. doi: 10.1016/j.mod.2018.06.004. Epub 2018 Jun 19.

11.

Imaging transcription factors dynamics with advanced fluorescence microscopy methods.

Verneri P, Romero JJ, De Rossi MC, Alvarez Y, Oses C, Guberman A, Levi V.

Mech Dev. 2018 Dec;154:60-63. doi: 10.1016/j.mod.2018.05.003. Epub 2018 May 16. Review.

12.

Inhibition of Cell Division and DNA Replication Impair Mouse-Naïve Pluripotency Exit.

Waisman A, Vazquez Echegaray C, Solari C, Cosentino MS, Martyn I, Deglincerti A, Ozair MZ, Ruzo A, Barañao L, Miriuka S, Brivanlou A, Guberman A.

J Mol Biol. 2017 Sep 1;429(18):2802-2815. doi: 10.1016/j.jmb.2017.06.020. Epub 2017 Jul 3.

PMID:
28684247
13.

AKT/GSK3β signaling pathway is critically involved in human pluripotent stem cell survival.

Romorini L, Garate X, Neiman G, Luzzani C, Furmento VA, Guberman AS, Sevlever GE, Scassa ME, Miriuka SG.

Sci Rep. 2016 Oct 20;6:35660. doi: 10.1038/srep35660.

14.

Generation of iPSC line iPSC-FH2.1 in hypoxic conditions from human foreskin fibroblasts.

Questa M, Romorini L, Blüguermann C, Solari CM, Neiman G, Luzzani C, Scassa MÉ, Sevlever GE, Guberman AS, Miriuka SG.

Stem Cell Res. 2016 Mar;16(2):300-3. doi: 10.1016/j.scr.2015.12.026. Epub 2016 Jan 4.

15.

Protein arginine Methyltransferase 8 gene is expressed in pluripotent stem cells and its expression is modulated by the transcription factor Sox2.

Solari C, Echegaray CV, Luzzani C, Cosentino MS, Waisman A, Petrone MV, Francia M, Sassone A, Canizo J, Sevlever G, Barañao L, Miriuka S, Guberman A.

Biochem Biophys Res Commun. 2016 Apr 22;473(1):194-199. doi: 10.1016/j.bbrc.2016.03.077. Epub 2016 Mar 21.

PMID:
27012206
16.

Manganese Superoxide Dismutase Gene Expression Is Induced by Nanog and Oct4, Essential Pluripotent Stem Cells' Transcription Factors.

Solari C, Vázquez Echegaray C, Cosentino MS, Petrone MV, Waisman A, Luzzani C, Francia M, Villodre E, Lenz G, Miriuka S, Barañao L, Guberman A.

PLoS One. 2015 Dec 7;10(12):e0144336. doi: 10.1371/journal.pone.0144336. eCollection 2015.

17.

Natural history of succinic semialdehyde dehydrogenase deficiency through adulthood.

Lapalme-Remis S, Lewis EC, De Meulemeester C, Chakraborty P, Gibson KM, Torres C, Guberman A, Salomons GS, Jakobs C, Ali-Ridha A, Parviz M, Pearl PL.

Neurology. 2015 Sep 8;85(10):861-5. doi: 10.1212/WNL.0000000000001906. Epub 2015 Aug 12.

18.

A therapy-grade protocol for differentiation of pluripotent stem cells into mesenchymal stem cells using platelet lysate as supplement.

Luzzani C, Neiman G, Garate X, Questa M, Solari C, Fernandez Espinosa D, García M, Errecalde AL, Guberman A, Scassa ME, Sevlever GE, Romorini L, Miriuka SG.

Stem Cell Res Ther. 2015 Jan 12;6:6. doi: 10.1186/scrt540.

19.

EDA-containing fibronectin increases proliferation of embryonic stem cells.

Losino N, Waisman A, Solari C, Luzzani C, Espinosa DF, Sassone A, Muro AF, Miriuka S, Sevlever G, Barañao L, Guberman A.

PLoS One. 2013 Nov 14;8(11):e80681. doi: 10.1371/journal.pone.0080681. eCollection 2013.

20.

Epilepsy and crossed cerebellar diaschisis with persistent cerebellar syndrome.

Fantaneanu TA, Tang V, Lum C, Guberman A.

Can J Neurol Sci. 2012 Jan;39(1):87-8. No abstract available.

PMID:
22384502
21.

Moral and social reasoning in autism spectrum disorders.

Shulman C, Guberman A, Shiling N, Bauminger N.

J Autism Dev Disord. 2012 Jul;42(7):1364-76. doi: 10.1007/s10803-011-1369-8.

PMID:
21960456
22.

Modulation of chromatin modifying factors' gene expression in embryonic and induced pluripotent stem cells.

Luzzani C, Solari C, Losino N, Ariel W, Romorini L, Bluguermann C, Sevlever G, Barañao L, Miriuka S, Guberman A.

Biochem Biophys Res Commun. 2011 Jul 15;410(4):816-22. doi: 10.1016/j.bbrc.2011.06.070. Epub 2011 Jun 15.

PMID:
21703227
23.

Induced pluripotent stem cells' self-renewal and pluripotency is maintained by a bovine granulosa cell line-conditioned medium.

Solari C, Losino N, Luzzani C, Waisman A, Bluguermann C, Questa M, Sevlever G, Miriuka S, Barañao L, Guberman A.

Biochem Biophys Res Commun. 2011 Jul 1;410(2):252-7. doi: 10.1016/j.bbrc.2011.05.126. Epub 2011 May 30.

PMID:
21651896
24.

Maintenance of murine embryonic stem cells' self-renewal and pluripotency with increase in proliferation rate by a bovine granulosa cell line-conditioned medium.

Losino N, Luzzani C, Solari C, Boffi J, Tisserand ML, Sevlever G, Barañao L, Guberman A.

Stem Cells Dev. 2011 Aug;20(8):1439-49. doi: 10.1089/scd.2010.0336. Epub 2011 Jan 12.

PMID:
21126164
26.

STAT5 transcriptional activity is impaired by LIF in a mammary epithelial cell line.

Granillo AR, Boffi JC, Barañao L, Kordon E, Pecci A, Guberman A.

Biochem Biophys Res Commun. 2007 May 11;356(3):727-32. Epub 2007 Mar 16.

PMID:
17382296
27.

Fibrous dysplasia of the skull base presenting acutely in an adult.

Amoozegar F, Guberman A.

Can J Neurol Sci. 2006 Aug;33(3):325-7. No abstract available.

PMID:
17001824
28.

Are there potential problems with generic substitution of antiepileptic drugs? A review of issues.

Crawford P, Feely M, Guberman A, Kramer G.

Seizure. 2006 Apr;15(3):165-76. Epub 2006 Feb 28. Review.

29.

Medical management of intractable epilepsy.

Starreveld E, Guberman A, Pillay N.

Adv Neurol. 2006;97:527-35. Review. No abstract available.

PMID:
16383160
30.

Differential diagnostic considerations in patients with intractable epilepsy.

Guberman A, Starreveld E.

Adv Neurol. 2006;97:497-515. Review. No abstract available.

PMID:
16383158
31.

The spectrum of intractable epilepsy: a proposed scale.

Starreveld E, Guberman A.

Adv Neurol. 2006;97:493-6. Review. No abstract available.

PMID:
16383157
32.

Epileptogenesis due to peripheral injury as a cause of focal epilepsy.

Spiller AE, Guberman A, Bartolomei F, Zifkin B, Andermann F.

Epilepsia. 2005 Aug;46(8):1252-5.

33.

Acute bilateral opercular strokes causing loss of emotional facial movements.

Sim VL, Guberman A, Hogan MJ.

Can J Neurol Sci. 2005 Feb;32(1):119-21.

PMID:
15825559
34.

Repression of 5-aminolevulinate synthase gene by the potent tumor promoter, TPA, involves multiple signal transduction pathways.

Guberman AS, Scassa ME, Cánepa ET.

Arch Biochem Biophys. 2005 Apr 15;436(2):285-96.

PMID:
15797241
35.

Vagus nerve stimulation in the treatment of epilepsy.

Guberman A.

CMAJ. 2004 Nov 9;171(10):1165-6. Review. No abstract available.

36.

Hepatic nuclear factor 3 and nuclear factor 1 regulate 5-aminolevulinate synthase gene expression and are involved in insulin repression.

Scassa ME, Guberman AS, Ceruti JM, Cánepa ET.

J Biol Chem. 2004 Jul 2;279(27):28082-92. Epub 2004 Apr 28.

37.

Quality of life after vagus nerve stimulation for intractable epilepsy: is seizure control the only contributing factor?

McLachlan RS, Sadler M, Pillay N, Guberman A, Jones M, Wiebe S, Schneiderman J.

Eur Neurol. 2003;50(1):16-9.

PMID:
12824707
38.
39.

Low-dose topiramate in adults with treatment-resistant partial-onset seizures.

Guberman A, Neto W, Gassmann-Mayer C; EPAJ-119 Study Group.

Acta Neurol Scand. 2002 Oct;106(4):183-9. Erratum in: Acta Neurol Scand. 2003 May;107(5):386.

PMID:
12225311
40.

Carbamazepine- induced hypertension.

Jette N, Veregin T, Guberman A.

Neurology. 2002 Jul 23;59(2):275-6.

PMID:
12136070
41.

Remacemide hydrochloride as an add-on therapy in epilepsy: a randomized, placebo-controlled trial of three dose levels (300, 600 and 800 mg/day) in a B.I.D. regimen.

Jones MW, Blume WT, Guberman A, Lee MA, Pillay N, Weaver DF, Veloso F, Holdich TA.

Seizure. 2002 Mar;11(2):104-13.

43.

Screening for and characterization of phospholipase A1 hypersecretory mutants of Tetrahymena thermophila.

Hartmann M, Guberman A, Florin-Christensen M, Tiedtke A.

Appl Microbiol Biotechnol. 2000 Sep;54(3):390-6.

PMID:
11030577
46.

Rash with lamotrigine: dosing guidelines.

Messenheimer JA, Guberman AH.

Epilepsia. 2000 Apr;41(4):488. No abstract available.

47.

Generic substitution for brand name antiepileptic drugs: a survey.

Guberman A, Corman C.

Can J Neurol Sci. 2000 Feb;27(1):37-43.

PMID:
10676586
48.

Hormonal contraception and epilepsy.

Guberman A.

Neurology. 1999;53(4 Suppl 1):S38-40. Review.

PMID:
10487513
49.

Symptomatic and asymptomatic visual loss in patients taking vigabatrin.

Daneshvar H, Racette L, Coupland SG, Kertes PJ, Guberman A, Zackon D.

Ophthalmology. 1999 Sep;106(9):1792-8.

PMID:
10485552
50.

Lamotrigine-associated rash: risk/benefit considerations in adults and children.

Guberman AH, Besag FM, Brodie MJ, Dooley JM, Duchowny MS, Pellock JM, Richens A, Stern RS, Trevathan E.

Epilepsia. 1999 Jul;40(7):985-91. Review.

Supplemental Content

Loading ...
Support Center